À propos de la société

A pioneer in its field, [Echosens](https://www.echosens.com/) significantly changed the practice of liver diagnosis with [**FibroScan®**](https://www.echosens.com/fibroscanliverexamination/), the non-invasive gold standard solution for comprehensive management of liver health. **FibroScan®** is recognized worldwide as the reference for liver fibrosis and liver steatosis assessment with more than 5 380+ peer-reviewed publications and 210+ international guidelines. Echosens has made FibroScan® available in over **127 countries** through its network of subsidiaries in Europe (Germany, Spain, UK, Italy), the United States and China (Shanghai, Shenzen and Hong Kong), enabling millions of liver examinations worldwide. **Echosens is shaping the future of liver health**. As a high-tech company, its connected solutions and services empower medical professionals to manage liver health for simpler, faster and better patient care. In today's **digital healthcare** environment and the silent epidemic of fatty liver disease ([**MASLD-MASH**](https://www.echosens.com/nafld-nash/)), Echosens is pursuing its international expansion and aims to make the liver check-up part of the health routine for at-risk patients, particularly people living with diabetes.